文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胃肠道癌中的外泌体长链非编码RNA:化疗耐药介质与治疗靶点

Exosomal long non-coding RNAs in gastrointestinal cancer: chemoresistance mediators and therapeutic targets.

作者信息

Li Chenhe, Xing Shunjia, Zhang Dechun, Li Ruoyu, Li Qian, Luo Hongliang, Liu Fangteng

机构信息

Department of Clinical Medicine, School of Queen Mary, Nanchang University, Jiangxi, 330006, People's Republic of China.

Department of Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, PR China.

出版信息

J Transl Med. 2025 Aug 8;23(1):889. doi: 10.1186/s12967-025-06878-5.


DOI:10.1186/s12967-025-06878-5
PMID:40781643
Abstract

Gastrointestinal (GI) cancer is a series of malignant cancer mainly affecting the GI tract. Chemotherapy is one of the most treatment strategies used in GI cancer treatment, especially in advanced cases. However, the challenge of chemoresistance significantly compromises treatment success, resulting in poorer clinical outcomes and increased metastatic potential. Long non-coding RNAs (lncRNAs) have emerged as important regulators of gene expression and are implicated in various disease processes. Recent research has demonstrated that lncRNAs can be packaged within exosomes, thereby facilitating intercellular communication and potentially transferring chemoresistance traits among cancer cells. This review focuses on the biogenesis and functional roles of exosomal lncRNAs in promoting chemoresistance across different GI cancers. We highlight specific lncRNAs, elucidate their mechanisms of action, and discuss innovative therapeutic strategies aimed at targeting these molecules in gastrointestinal malignancies. By exploring these intricate interactions, we aim to identify novel approaches to overcome chemoresistance and improve the efficacy of treatments for GI cancer.

摘要

胃肠道(GI)癌是一系列主要影响胃肠道的恶性肿瘤。化疗是胃肠道癌治疗中最常用的治疗策略之一,尤其是在晚期病例中。然而,化疗耐药性这一挑战显著影响治疗效果,导致临床结果较差且转移潜力增加。长链非编码RNA(lncRNAs)已成为基因表达的重要调节因子,并参与各种疾病进程。最近的研究表明,lncRNAs可以包裹在外泌体中,从而促进细胞间通讯,并可能在癌细胞之间传递化疗耐药性特征。本综述聚焦于外泌体lncRNAs在不同胃肠道癌中促进化疗耐药性的生物发生及功能作用。我们重点介绍特定的lncRNAs,阐明其作用机制,并讨论针对胃肠道恶性肿瘤中这些分子的创新治疗策略。通过探索这些复杂的相互作用,我们旨在确定克服化疗耐药性和提高胃肠道癌治疗效果的新方法。

相似文献

[1]
Exosomal long non-coding RNAs in gastrointestinal cancer: chemoresistance mediators and therapeutic targets.

J Transl Med. 2025-8-8

[2]
Unveiling the functional paradigm of exosome-derived long non-coding RNAs (lncRNAs) in cancer: based on a narrative review and systematic review.

J Cancer Res Clin Oncol. 2023-11

[3]
Role of long non-coding RNAs in neurofibromatosis and Schwannomatosis: pathogenesis and therapeutic potential.

Epigenomics. 2024

[4]
Exosomal long non-coding RNAs in human malignancies: biological functions and clinical applications.

Med Oncol. 2025-6-24

[5]
The role of long non-coding RNAs in lung cancer metastasis: Molecular mechanisms, pathogenesis and clinical implications.

Clin Transl Med. 2025-8

[6]
Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance.

Naunyn Schmiedebergs Arch Pharmacol. 2025-1-18

[7]
Unveiling the power of exosomal non-coding RNAs: key drivers of lung cancer progression in the tumor microenvironment.

Med Oncol. 2025-7-1

[8]
Getting the GIST of long non-coding RNA.

Biochim Biophys Acta Rev Cancer. 2025-9

[9]
Management of urinary stones by experts in stone disease (ESD 2025).

Arch Ital Urol Androl. 2025-6-30

[10]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

本文引用的文献

[1]
Astaxanthin biofortification enhances tobacco tolerance to lead stress through boosting antioxidant defense, reducing Pb accumulation, and modulating detoxification pathways.

J Adv Res. 2025-7-23

[2]
Long non-coding RNAs: Emerging regulators of invasion and metastasis in pancreatic cancer.

J Adv Res. 2025-2-9

[3]
Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.

Pharmaceutics. 2024-8-30

[4]
Progress of Exosomal LncRNAs in Pancreatic Cancer.

Int J Mol Sci. 2024-8-8

[5]
Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases.

MedComm (2020). 2024-7-15

[6]
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer.

Int J Mol Sci. 2024-5-29

[7]
CRISPRi screens identify the lncRNA, , as a multifunctional locus regulating macrophage differentiation and inflammatory signaling.

Proc Natl Acad Sci U S A. 2024-5-28

[8]
M2 Tumor-Associated Macrophages-Derived Exosomal MALAT1 Promotes Glycolysis and Gastric Cancer Progression.

Adv Sci (Weinh). 2024-6

[9]
LncRNA HOTTIP facilitated tumor growth stimulating the hnRNPA2B1/DKK1/Wnt/β-catenin regulatory axis in hepatocellular carcinoma.

Genes Dis. 2023-7-4

[10]
An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.

Front Immunol. 2024

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索